Gilead Sciences (GILD) has been in the spotlight for various reasons. The company's strong financial performance boosted by robust pipeline and impressive Q1 growth, despite missing revenue estimates, have contributed positively to the stock. Experts have labeled it a
strong value stock and a good bet for the long term, with a top socially responsible dividend yield of 2.9%. Analysts from
Jefferies and
Citi maintained buy ratings citing its steady pipeline. GILD has outperformed the
S&P 500 and its medical peers this year, however, reported a dip recent times despite market gains.
Gilead's Trodelvy, with Keytruda, has demonstrated a significant reduction in breast cancer risk in trials. The company reported positive results from a phase 3 Trodelvy study, boosting investor optimism. However, declining sales of COVID-19 and cancer drugs have impacted the revenue. The drop in stock despite market gains and insider sell off are noted. With overall positive outlook and robust pipeline, this trending stock has led to unusual options alert, indicating smart money piling in. The
HIV prevention drug is reported to be on track for mid-June, further adding a promising future aspect.
Gilead Sciences GILD News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Thu, 05 Jun 2025 18:07:06 GMT -
Rating 8
- Innovation 5
- Information 7
- Rumor 4
